Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
Daniel Ebrahimi-FakhariDavid Neal FranzPublished in: Expert opinion on pharmacotherapy (2020)
mTOR inhibitors have largely replaced surgery as the primary modality for the management of SEGAs. Surgical treatment is largely limited to tumors that present with acute hydrocephalus and increased intracranial pressure. Patients with TSC should undergo periodic screening with CT or preferably MRI scans of the brain from childhood to approximately age 25 to identify SEGAs which require treatment. In addition to avoiding potential morbidity associated with surgical resection, mTOR inhibitors have the potential to improve the clinical status of tuberous sclerosis patients generally.
Keyphrases
- contrast enhanced
- giant cell
- end stage renal disease
- computed tomography
- magnetic resonance imaging
- cell proliferation
- ejection fraction
- minimally invasive
- newly diagnosed
- chronic kidney disease
- liver failure
- peritoneal dialysis
- coronary artery bypass
- prognostic factors
- white matter
- multiple sclerosis
- positron emission tomography
- resting state
- subarachnoid hemorrhage
- atrial fibrillation
- image quality
- brain injury
- coronary artery disease
- percutaneous coronary intervention
- acute respiratory distress syndrome
- climate change
- optical coherence tomography
- childhood cancer
- aortic dissection
- early life
- smoking cessation